Henney Nominated for FDA Commissioner

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 8
Volume 7
Issue 8

WASHINGTON--President Clinton has nominated Jane E. Henney, MD, vice president for health sciences, University of New Mexico, as the new FDA Commissioner. She would replace David M. Kessler, MD, who resigned more than a year ago and is now dean of the Yale University School of Medicine.

WASHINGTON--President Clinton has nominated Jane E. Henney, MD, vice president for health sciences, University of New Mexico, as the new FDA Commissioner. She would replace David M. Kessler, MD, who resigned more than a year ago and is now dean of the Yale University School of Medicine.

Dr. Henney, a cancer specialist, has served in government under every president since Jimmy Carter. She was the FDA’s deputy commissioner for operations from 1992 to 1994.

Her nomination won warm praise from many in the medical and public health fields, including Health and Human Services Secretary Donna E. Shalala, PhD. The Secretary called Dr. Henney "a talented manager" with "the solid medical and academic credentials that are needed to understand the burgeoning field of biomedical research."

However, several conservative Republicans have indicated their opposition to Dr. Henney. They want to know specifically if she had anything to do with the FDA’s decision to allow testing of the abortion drug RU-486.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
6371178759112
Focused, high-dose radiotherapy doses may prolong survival and the interval to subsequent therapy for patients with advanced prostate cancer.
Data show increasing use of proton therapy overall but widening gaps in populations who have access to this treatment, says Curtiland Deville Jr., MD.
Related Content